文章核心观点 - 公司决定分离生育和肿瘤业务，预计使两个业务实现股东价值最大化 [1] 公司战略调整 - 公司于2025年4月14日更名为“INVO Fertility, Inc.”，纳斯达克股票代码将尽快变更为“IVF” [2] - 公司剥离生育和肿瘤业务，专注生育市场，开展生育诊所的建立、收购和运营及INVOcell设备的分销 [1][3] - 公司计划剥离全资子公司NAYA Therapeutics Inc.的多数股权，保留少数股权以从其双功能抗体临床开发的潜在价值增值中获益 [4] 公司业务规划 - 公司将利用威斯康星州、阿拉巴马州和佐治亚州的运营中心，在美国收购和建设新的生育中心 [5] 公司财务情况 - 公司此前申请延期提交截至2024年12月31日的年度报告（Form 10 - K），目前正在完成该财年的财务报表和其他披露工作 [5] 公司业务介绍 INVO Fertility, Inc. - 是一家医疗服务生育公司，致力于为有需要的患者提供辅助生殖技术护理 [6] - 主要商业策略是建立、收购和运营生育诊所，包括提供INVOcell医疗设备支持的阴道内培养程序的“INVO Centers”和美国的体外受精诊所 [6] - 在美国有两个运营中的INVO Centers和一个体外受精诊所，并继续向第三方生育诊所销售和分销INVOcell技术解决方案 [6] NAYA Therapeutics, Inc. - 是一家临床阶段的生物制药公司，致力于通过开发下一代双功能抗体改善肿瘤治疗效果 [7] - 产品组合包括用于治疗肝癌的NY - 303、旨在成为肝癌市场首个PD - 1 x VEGF双功能抗体的NY - 500和用于治疗多发性骨髓瘤的NY - 338 [7]

文章核心观点 公司宣布将生育和肿瘤业务分离，预计使两个业务实现股东价值最大化，分离后公司专注生育市场，剥离肿瘤子公司多数股权并保留少数权益 [1][4] 公司战略调整 - 公司将生育和肿瘤业务分离，预计使两个业务实现股东价值最大化 [1] - 公司于2025年4月14日更名为“INVO Fertility, Inc.”，纳斯达克股票代码将尽快变更为“IVF” [2] - 公司剥离全资子公司NAYA Therapeutics Inc.多数股权，保留少数权益以从其双功能抗体临床开发潜在价值增值中获益 [4] 生育业务规划 - 公司回归专注生育市场，开展建立、收购和运营新生育诊所及分销FDA批准的INVOcell设备业务 [3] - 公司将利用威斯康星州、阿拉巴马州和佐治亚州运营中心，在美国收购和建设新中心 [5] 公司业务介绍 INVO Fertility, Inc. - 是一家医疗服务生育公司，致力于为有需要患者提供辅助生殖技术护理 [6] - 主要商业策略是建立、收购和运营生育诊所，包括“INVO Centers”和美国盈利体外受精诊所 [6] - 拥有两个运营中的INVO Centers和一个IVF诊所，还销售和分销INVOcell技术解决方案 [6] NAYA Therapeutics, Inc. - 是一家临床阶段生物制药公司，致力于通过开发下一代双功能抗体改善肿瘤治疗结果 [7] - 产品组合包括用于治疗肝癌的NY - 303、旨在成为肝癌市场首个PD - 1 x VEGF的NY - 500和用于治疗多发性骨髓瘤的NY - 338 [7] 其他信息 - 公司此前申请延期提交2024年12月31日年度报告Form 10 - K，正在完成该财年财务报表和其他披露 [5]

SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 ...

SARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, proudly supports the U.S. President’s recent executive order aimed at reducing the cost of IVF and expanding access to fertility services. Th ...

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting sch ...

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common ...

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of commo ...

•  PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications •  NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced that it is expanding its bifunctional antibody pipeline to include ...

• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that it is expanding its bifunctional antibody pipeline to include ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39701 NAYA Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 20-403620 ...